Duration of Medication Treatment for Opioid-Use Disorder and Risk of Overdose among Medicaid Enrollees in 11 States: A Retrospective Cohort Study


Medication for opioid use disorder (MOUD) reduces harms associated with opioid use disorder (OUD), including risk of overdose. Understanding how variation in MOUD duration influences overdose risk is important as health-care payers increasingly remove barriers to treatment continuation (e.g. prior authorization). This study measured the association between MOUD continuation, relative to discontinuation, and opioid-related overdose among Medicaid beneficiaries.

Senior Policy Analyst Shamis Mohamoud was part of the Medicaid Outcomes Distributed Research Network (MODRN) team of authors of this article published in Addiction.

Read the article online.